Who are Cilostazol Tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pletaal SR capsule, Probucol and Cilostazol, Milrinone Lactate, Cilostazol group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cilostazol-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Cilostazol Tablets — Competitive Intelligence Brief

Cilostazol Tablets (Cilostazol Tablets) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase-3 inhibitor. Area: Cardiovascular.

marketed Phosphodiesterase-3 inhibitor PDE-3 (Phosphodiesterase-3) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Cilostazol Tablets (Cilostazol Tablets) — Gyeongsang National University Hospital. Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Cilostazol Tablets TARGET	Cilostazol Tablets	Gyeongsang National University Hospital	marketed	Phosphodiesterase-3 inhibitor	PDE-3 (Phosphodiesterase-3)
Pletaal SR capsule	Pletaal SR capsule	Korea Otsuka Pharmaceutical Co., Ltd.	marketed	Phosphodiesterase-3 inhibitor	PDE-3 (phosphodiesterase-3)
Probucol and Cilostazol	Probucol and Cilostazol	Otsuka Beijing Research Institute	marketed	Antioxidant/lipid-lowering agent combined with phosphodiesterase-3 inhibitor	Probucol: lipid peroxidation inhibitor; Cilostazol: phosphodiesterase-3 (PDE-3)
Milrinone Lactate	Milrinone Lactate	Pfizer Inc.	marketed	Inotropic agent; Phosphodiesterase-3 inhibitor; Vasodilator	Phosphodiesterase-3 (PDE-3) enzyme
Cilostazol group	Cilostazol group	Otsuka Beijing Research Institute	marketed	Phosphodiesterase-3 inhibitor	PDE-3 (Phosphodiesterase-3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase-3 inhibitor class)

Gyeongsang National University Hospital · 1 drug in this class
Korea Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class
Otsuka Beijing Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cilostazol Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/cilostazol-tablets. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab